1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say

CEO Robert Blum Talked To Scrip

 
• By Jessica Merrill

The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.

Detailed results from Cytokinetics, Inc.'s Phase III SEQUOIA-HCM trial testing its cardiac myosin inhibitor aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM) have led some cardiologists to conclude the drug could have a competitive edge over Bristol Myers Squibb’s rival myosin inhibitor Camzyos (mavacamten).

Key Takeaways

  • Cardiologists at Heart Failure 2024 were enthusiastic about Cytokinetics’ cardiac myosin inhibitor aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM).

Cytokinetics presented the data in a late-breaking session at the International Congress of the European Society of Cardiology’s Heart Failure...

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.